• Bardoxolone Methyl: Applied Workflows for Redox Pathway Modu

  2026-07-07

  Bardoxolone methyl (CDDO methyl ester) empowers researchers to dissect and modulate the Nrf2 and NF-kB pathways, enabling precise control of oxidative stress and inflammation in cancer and kidney disease models. This article delivers stepwise protocols, troubleshooting strategies, and actionable insights for maximizing the compound's experimental impact, grounded in the latest redox biology breakthroughs.

• Lanabecestat (AZD3293): Protocols for Precision BACE1 Inhibi

  2026-07-07

  Lanabecestat (AZD3293) offers nanomolar-precision BACE1 inhibition, empowering Alzheimer’s disease research with robust amyloid-beta modulation and reliable blood-brain barrier penetration. This guide delivers workflow enhancements, troubleshooting tips, and actionable evidence for maximizing translational impact with APExBIO’s trusted compound.

• BFH772 (VEGFR2 inhibitor): Selectivity, Protocols, and Scope

  2026-07-06

  BFH772 is a highly selective VEGFR2 inhibitor for research requiring precise modulation of VEGFR2-mediated angiogenesis, particularly in tumor model workflows. It is unsuitable for protocols dependent on water-soluble compounds or those needing broad-spectrum kinase inhibition. Researchers benefit from detailed QC documentation and must account for solubility and storage constraints in assay design.

• BFH772 (VEGFR2 Inhibitor): Technical Use and Protocol Parame

  2026-07-06

  BFH772 is a highly selective VEGFR2 inhibitor designed for targeted modulation of VEGFR2-driven angiogenesis, especially in tumor model systems. It is not recommended for workflows requiring water solubility or broad-spectrum kinase inhibition, making it best suited for precise studies of VEGFR2-specific pathways.

• Entecavir (BMS200475): Precision Inhibition of HBV Replicati

  2026-07-05

  Entecavir (BMS200475) stands out as a nanomolar-potency, highly selective inhibitor for chronic hepatitis B virus replication, including challenging lamivudine-resistant strains. This guide details experimental workflow optimizations, resistance risk insights, and hands-on troubleshooting strategies for maximizing reproducibility in HBV research.

• Data-Driven Design of Optimized Kinase Inhibitor Libraries

  2026-07-04

  Moret et al. (2019) introduce a cheminformatics framework for analyzing and constructing optimized small-molecule libraries, advancing selectivity and target coverage for kinase inhibitors. Their findings offer actionable strategies for assembling rational, mechanism-focused compound collections that can accelerate discovery in translational cancer research.

• Cabozantinib (XL184): Optimizing Phosphoproteomic RCC Workfl

  2026-07-03

  Cabozantinib (XL184) enables precision modeling of kinase pathway adaptation in renal cell carcinoma, transforming chronic inhibitor studies with advanced phosphoproteomic workflows. This guide distills timescale-dependent insights, protocol enhancements, and troubleshooting tactics to boost experimental reproducibility and biological relevance.

• Trametinib (GSK1120212): Applied Workflows in Oncology Resea

  2026-07-03

  Trametinib (GSK1120212) empowers oncology researchers to dissect MEK-ERK signaling dynamics and model drug resistance, with precise cell cycle and apoptosis modulation in both cell-based and in vivo systems. This guide translates recent breakthroughs into actionable protocols and troubleshooting strategies, ensuring robust and reproducible outcomes in cancer research.

• FLT3–TAZ Axis: Overcoming Drug Resistance in BP-CML

  2026-07-02

  Shin et al. uncover a critical role for FLT3 signaling in driving drug resistance during blast phase chronic myeloid leukemia. Their multi-omics approach reveals how FLT3 activation rewires survival pathways, offering new therapeutic targets to tackle resistance beyond BCR::ABL1 mutations.

• TCAIM Regulates OGDH Levels to Control Mitochondrial Metabol

  2026-07-02

  Wang et al. (2025) identify TCAIM as a DNAJC co-chaperone that specifically reduces mitochondrial a-ketoglutarate dehydrogenase (OGDH) protein levels through HSPA9 and LONP1, leading to suppressed OGDH complex activity and altered cellular metabolism. This discovery advances our understanding of mitochondrial proteostasis and presents a novel post-translational mechanism with implications for metabolic research.

• MLN8237 (Alisertib): Reliable Aurora A Inhibitor for Cancer

  2026-07-01

  MLN8237 (Alisertib) (SKU A4110) is a highly selective Aurora A kinase inhibitor, validated for apoptosis induction and tumor growth inhibition studies in cancer biology. This article guides researchers through real-world experimental challenges, demonstrating how MLN8237 (Alisertib) supports reproducible, data-driven workflows for cell-based assays.

• Temporal Transcriptomics Identifies Host Targets for Anti-EB

  2026-07-01

  This study integrates time-series transcriptomic profiling and systems biology to reveal dynamic host gene modules exploited by Ebola virus (EBOV) during infection. By linking these modules to druggable host factors, the authors identify actionable therapeutic targets, validate them functionally, and demonstrate the antiviral effect of host-directed agents such as Sorafenib.

• Omeprazole (A2845): Technical Workflow Guide for H+,K+-ATPas

  2026-06-30

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor used to model and modulate gastric acid secretion in controlled research workflows. It is designed for preclinical studies investigating gastric acid-related disorders, antiulcer activity, and proton pump inhibition mechanisms. This compound is not suitable for diagnostic or medical applications and should be handled according to research-grade standards.

• Deferiprone and Iron Stress: Advanced Insights for Assay Des

  2026-06-30

  Explore how Deferiprone, a leading iron chelator, enables precise modulation of iron-dependent pathways in research. This article uniquely dissects recent metabolomic findings and offers actionable guidance for optimizing apoptosis and metabolic assays.

• BFH772 (VEGFR2 Inhibitor): Technical Use and Workflow Parame

  2026-06-29

  BFH772 is a potent, highly selective VEGFR2 inhibitor designed for precise modulation of VEGFR2-mediated angiogenesis, especially in tumor model research. It is not suitable for workflows requiring water solubility or broad-spectrum kinase inhibition but offers strong selectivity and solubility in DMSO or ethanol, making it ideal for organic-solvent-compatible assays.

15750 records 1/1050 page Next 12345 下5页 Last page